Vasculogenic mimicry and mosaic vessels and targeted therapy in renal cell carcinoma.
10.3881/j.issn.1000-503X.2011.04.023
- Author:
Jian-hua DENG
1
;
Han-zhong LI
Author Information
1. Department of Urology, PUMC Hospital, CAMS and PUMC, Beijing, China.
- Publication Type:Journal Article
- MeSH:
Carcinoma, Renal Cell;
blood supply;
therapy;
Humans;
Kidney Neoplasms;
blood supply;
therapy
- From:
Acta Academiae Medicinae Sinicae
2011;33(4):462-467
- CountryChina
- Language:Chinese
-
Abstract:
Renal cell carcinoma is one of the most common malignant tumors of urinary system. The annual incidence rate is approximately 17.9/100 000 populations, and there is a continually rising trend in number of new diagnosis. Metastatic and high-risk renal cell cancer is associated with a poor prognosis and is resistant to traditional chemotherapy and/or radiotherapy. Although cytokine-based therapies (interferon and interleukin-2) have been widely used, their effectiveness remained unsatisfactory due to their low response rates and short survival. Drugs targeting anti-angiogenesis pathways have shown benefits in relapse-free survival. In this review, we introduce the recent advances in the treatment of renal cancer, especially the application of vasculogenic mimicry and mosaic vessels. Although targeted therapies with anti-angiogenic properties have proposed new treatment criteria for advanced renal cell carcinoma, new drugs or new combinations are needed to improve the clinical efficacy and minimize adverse effects.
